

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of Schwartz, et al.

Serial No. 10/695,509

Examiner: Fetterolf, Brandon J.

Filed: October 28, 2003

Art Unit: 1642

For: METHODS FOR PREVENTION AND TREATMENT OF CANCER

DECLARATION UNDER 37 CFR 1.132

I, Gary G. Schwartz, Ph.D., M.P.H, Ph.D., the undersigned, am a citizen and resident of the United States, and hereby declare the following:

WHEREAS, I received a B.A degree in psychology from Pomona College in Claremont, California (1978); a Ph.D. in Biological Psychology from the State University of New York Downstate Medical Center in 1985 and, at the University of North Carolina at Chapel Hill, received a Master's in Public health in 1988, completed a Postdoctoral Fellowship in Cancer Epidemiology in 1989, and received a Ph.D. in epidemiology in 1993; and

WHEREAS, I have authored or co-authored more than 50 peer-reviewed research papers published in scientific journals and multiple abstracts, book chapters, and presentations in my field of expertise (a representative list of which is attached hereto as Appendix A); and

WHEREAS, I currently hold the joint positions of:

- Associate Professor (tenured), Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC; and
- Associate Professor, Department of Epidemiology & Prevention, Wake Forest University School of Medicine; and

- Scientific Director, Prostate Cancer Center of Excellence, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC.

WHEREAS, I previously held the positions of:

- Associate Professor, Department of Epidemiology & Public Health, University of Miami School of Medicine, Miami FL (June 1997-June 1999);
- Research Associate Professor, Department of Epidemiology & Public Health, University of Miami School of Medicine, Miami FL (August 1994-May 1997);
- Assistant Professor, Department of Clinical Epidemiology and Preventive Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA (May 1991-July 1994); and

WHEREAS, I am a named inventor on the subject patent application, and have read and reviewed the subject patent application, as filed and amended, as well as the instant Office Action and the references cited therein.

NOW THEREFORE, BEING established as an expert in the field of cancer research relating to the subject matter of the claimed invention, I make the following statements and render my opinion based on my knowledge of the inventions and in view of my experience and expertise:

THAT, the capability and the operability of the claimed physiological doses of 25-OHD3 to inhibit the proliferation of cancer or tumor cells, including prostate cancer cells, has been clearly demonstrated.

A scientific publication which clarifies the successful use of 25-OH Vitamin D3 to inhibit cancer cell proliferation is Lou, Y-R, Laaksi I, Syväla, et al., "25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB Journal, 2004, Feb 18 (2):332-344", published online December 4, 2003. This Lou, et al., publication is incorporated by reference into this Declaration, and a copy is being submitted herewith.

The Office Action cites certain references, namely, Ma, et al., Hsu, et al., and Whitlach, et al., as showing that 1-OHase activity is reduced in prostate epithelial cells. Several authors, including those cited in the Office Action, have opined that the reduced activity of 1-OHase in these epithelial cells may make 25-Hydroxyvitamin D3 ineffective as a treatment for prostate cancer. However, as Lou et al., teach, although several

papers have focused on the epithelial cells in the prostate, approximately half of the prostate is composed of stromal cells. The stromal component of the prostate “plays a critical role not only in the regulation of normal epithelial differentiation but also the progression of tumorigenesis.” Lou et al. demonstrate that stromal cells from primary cultures of prostate cancer possess 1-OHase and that the administration of 25-Hydroxyvitamin D3 at physiological concentrations (100 – 250 nM), which is within the range claimed in the current patent application, reduces cell proliferation of these cells.

As background, Lou et al teach:

“... epithelial and stromal cells are present in approximately equal numbers in human prostate and stromal cells are the first to face hormonal agents derived from the circulation. Thus, stromal cells may play a central role in the metabolism and action of vitamin D3 compounds in prostate organ. However, there is cumulative evidence that the prostatic stromal component plays a critical role not only in the regulation of normal epithelial differentiation but also the progression of tumorigenesis. Studies in vitro and in vivo have shown that prostatic fibroblasts can affect tumor cell growth and progression, the type and the extent of the response depending on both degree of malignancy of epithelial cells and pathologic extent of fibroblast origin. For instance, in the study by Olumi et al. prostatic fibroblasts derived from malignant human tissue were found to enhance growth, retard cell death and alter histology of initiated but not tumorigenic epithelial cells. Normal prostatic fibroblasts have also been reported to reduce death of LNCaP cells [a prostate cancer cell line] in vitro coculture and in vivo xenograft systems. Hence, suppression or stimulation of prostatic fibroblast could affect cancer cell growth.”

In their well-described paper, Lou et al show clearly that, using two human prostate stromal primary cultures (P29SN and P32S cells), “25-OHD3 was found at physiological concentrations of 100-250 nM to inhibit the growth of primary cultures” (Abstract). These findings are shown graphically in Figure 2 of their paper.

The authors conclude that the fact that 25-OHD₃ at physiological concentrations targets gene expression and suppresses cell growth in prostate cancer cells supports the view that this may represent “a potent anticancer therapy.”

The demonstration of anti-tumor activity by 25-OHD shown by Lou, *et al.*, contrasts with the view expressed by Ma, *et al.*, that 25-OHD3 would be ineffective as therapy. As noted above, the view of Ma, *et al.*, is based on the reduced expression of 1-OHase activity in epithelial cells only. Ma, *et al.*, appear unaware of the findings of Lou, *et al.*, which were published prior to the work of Ma, *et al.*, in late 2004 (the online publication date for Lou *et al* was in December 2003, paper publication in February 2004), both of which carry publication dates well after the effective filing date of the subject application.

Notably, these experimental results provided in the Lou, *et al.*, publication establish a "clinical correlation" between the effective amount provided and the tumor or cancer inhibition, as claimed. Moreover, the experiments of Lou, *et al.*, were performed in primary cultures of cells obtained from individual men with cancer, and are thus cells within hours of being *in situ* and are a much closer model to the living individual than immortalized cell lines transformed from highly selected cells.

THEREFORE, it is my expert opinion that Lou, *et al.*, directly contradict the speculative conclusions of the cited Ma, *et al.*, Hsu, *et al.*, and Whitlach, *et al.*, references, and establish that cancer and tumor cells are inhibited by the physiological doses of 25-OHD3, as claimed.


I HEREBY DECLARE THAT ALL STATEMENTS MADE HEREIN OF MY OWN KNOWLEDGE ARE TRUE AND THAT ALL STATEMENT MADE ON INFORMATION AND BELIEF ARE BELIEVED TO BE TRUE; AND FURTHER THAT THESE STATEMENTS WERE MADE WITH THE KNOWLEDGE THAT WILLFUL FALSE STATEMENTS AND THE LIKE SO MADE ARE PUNISHABLE BY FINE OR IMPRISONMENT, OR BOTH, UNDER 18 U.S.C. 1001 AND THAT SUCH WILLFUL FALSE STATEMENTS MAY JEOPARDIZE THE VALIDITY OF THE PATENT APPLICATION OR ANY PATENT ISSUED THEREON.

Further, Declarant sayeth naught.

Date:

September 4 2009

By:


Gary G. Schwartz, Ph.D., M.P.H., Ph.D.

APPENDIX A

PUBLICATIONS AUTHORED OR CO-AUTHORED BY GARY G. SCHWARTZ, PhD, MPH, PhD

Refereed Journal Articles

1. Cohen SW, Sherman M, **Schwartz GG**, Banko W, Cohen H, Mahl C. Lacrimal outflow patency demonstrated by chemiluminescence. Archives of Ophthalmology. 1980;98:127-128.
2. **Schwartz GG**, Rosenblum LA. Novelty, arousal and nasal marking in the squirrel monkey. Behavioral and Neural Biology. 1980;28:116-122.
3. **Schwartz GG**, Rosenblum LA. Allometry of primate hair density and the evolution of human hairlessness. American Journal of Physical Anthropology 1981;55:9-12.
4. **Schwartz GG**, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis) Anticancer Research 1990;10:1307-1311.
5. Hanchette CL, **Schwartz GG** (*corresponding author*). Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-2869.
6. **Schwartz GG**. Multiple sclerosis and prostate cancer: What do their similar geographies suggest? Neuroepidemiology 1992;11:244-254.
7. **Schwartz GG**, Oeler T, Uskokovic M, Bahnson RR. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs. Anticancer Research. 1994;14:1077-1081.
8. **Schwartz GG**, Hill CC, Oeler T, Becich MJ, Bahnson RR. 1,25-Dihydroxy-16-ene-23-yne-vitamin D₃ and prostate cancer cell proliferation *in vivo*. Urology 1995, 46:365-369.
9. Osborn JL, **Schwartz GG**, Smith DC, Bahnson RR, Day R, Trump DL. Phase II trial of oral 1,25-Dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urologic Oncology 1995;1:195-198.
10. Konety BR, **Schwartz GG**, Acierno JS, Becich MJ, Getzenberg RH. The role of vitamin D in normal prostatic growth and development. Cell Growth & Differentiation 1996;7:1563-1570.
11. **Schwartz GG**, Wang M-H, Zhang M, Singh RK, Siegal GP. 1 α , 25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiology, Biomarkers & Prevention 1997;6:727-732.
12. Zhuang S-H, **Schwartz GG**, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cells. Molecular and Cellular Endocrinology 1997, 126:83-90.
13. **Schwartz GG**. Multiple myeloma: Cluster, clues and dioxins. Cancer Epidemiology, Biomarkers and Prevention. 1997, 6:49-56.

14. **Schwartz GG**, Skinner HG, Duncan R. Solid waste and pancreatic cancer. International Journal of Epidemiology 1998; 27:781-787.
15. **Schwartz GG**, Whitlach LW, Chen TC, Lokeshwar B, Holick MF. Human prostate cells synthesize 1,25-Dihydroxyvitamin D₃ from 25-Hydroxyvitamin D₃. Cancer Epidemiology, Biomarkers, and Prevention 1998;7:391-395.
16. Lokeshwar BL, **Schwartz GG**, Selzer MG, Burnstein KL, Zhuang S-H, Block NL, Binderup L. Inhibition of prostate cancer metastasis *in vivo*: A comparison of 1,25-Dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiology, Biomarkers & Prevention, 1999;8:241-248.
17. John EM, **Schwartz GG**, Dreon DM, Koo, J. Vitamin D and breast cancer risk: The NHANES I Epidemiologic Follow-up Study, 1971-1975 to 1992. Cancer Epidemiology, Biomarkers & Prevention 1999;8:399-406.
18. Barreto A, **Schwartz GG**, Woodruff R, Cramer SD. 25-Hydroxyvitamin D₃, the prohormonal form of 1,25-Dihydroxyvitamin D₃, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiology, Biomarkers & Prevention 2000;9:265-270.
19. Chen TC, **Schwartz GG**, Burnstein KL, Lokeshwar BL, Holick MF. The use of 25-Hydroxyvitamin D₃ and 19-nor-1,25-Dihydroxyvitamin D₂ as therapeutic agents for prostate cancer. Clinical Cancer Research 2000;6:901-908.
20. **Schwartz GG**, Reis IM. Is cadmium a cause of human pancreatic cancer? Cancer Epidemiology, Biomarkers & Prevention 2000;9:139-145.
21. **Schwartz GG**. Hypothesis: Does ochratoxin A cause testicular cancer? Cancer Causes & Control 2002; 13:91-100.
22. Perez-Stable CM, **Schwartz GG**, Farinas A, Finegold M, Binderup L, Howard GA, Roos BA. The Gy/T-15 transgenic mouse model of androgen-independent prostate cancer: Target cells of carcinogenesis and the effect of the vitamin D analogue, EB 1089. Cancer Epidemiology, Biomarkers and Prevention 2002, 11:555-563.
23. Whitlatch LW, Young MV, **Schwartz GG**, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC. 25-Hydroxyvitamin D-1-alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. Journal of Steroid Biochemistry & Molecular Biology 2002, 81:135-140.
24. **Schwartz GG**, Il'yasova D, Ivanova A. Urinary cadmium, impaired glucose tolerance, and diabetes in the NHANES III. Diabetes Care 2003:468-470.
25. Molnar I, Kute T, Willingham MC, Powell BL, Dodge WH, **Schwartz GG** (*corresponding author*). 19-nor-1 α ,25-dihydroxyvitamin D₂ (paricalcitol): Effects on clonal proliferation, differentiation and apoptosis in human leukemic cell lines. Journal of Cancer Research and Clinical Oncology 2003, 129:35-42.
26. Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, **Schwartz GG**. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results in Cancer Research 2003, 164: 273-288.

27. Dunlap N, **Schwartz GG**, Eads D, Cramer SD, Sherk AB, John V, Koumenis C. $1\alpha,25(\text{OH})_2\text{D}$ (calcitriol) and its analogue, $19\text{-nor-}1\alpha\text{-}25(\text{OH})_2\text{D}_2$, potentiate the effects of ionising radiation on prostate cancer cells. British Journal of Cancer 2003, 89: 746-753.
28. **Schwartz GG**, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF, Koumenis C. Pancreatic cancer cells express $25\text{-Hydroxyvitamin D-}1\alpha\text{-Hydroxylase}$ and their proliferation is inhibited by the prohormone $25\text{-Hydroxyvitamin D}_3$. Carcinogenesis 2004, 25: 1015-1026.
29. Young MV, **Schwartz GG**, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF, Chen TC. The prostate $25\text{-Hydroxyvitamin D-}1\alpha\text{-Hydroxylase}$ is not influenced by parathyroid hormone and calcium: Implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004, 25: 967-971.
30. John EM, Dreon DM, Koo J, **Schwartz GG** (*corresponding author*) Residential sunlight exposure is associated with a decreased risk of prostate cancer. Journal of Steroid Biochemistry & Molecular Biology 2004, 89-90:549-552.
31. Molnar I, Kute T, Willingham MC, Powell BL, **Schwartz GG** (*corresponding author*). $19\text{-nor-}1\alpha,25\text{-dihydroxyvitamin D}_2$ (paricalcitol) inhibits the proliferation of human leukemic cells at clinically-achievable levels. Journal of Steroid Biochemistry & Molecular Biology 2004, 89-90:539-543.
32. Sahmoun AE, Case LD, Chavour S, Kareem S, **Schwartz GG**. Hypertension and risk of brain metastasis from small cell lung cancer: A retrospective follow-up study. Anticancer Research 2004, 24: 3115-3120.
33. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, Kristal A, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JL, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, **Schwartz GG**, Ford LG, Collman CA. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute 2005, 97: 94-102.
34. **Schwartz GG**. Cuáles son las causas del cáncer de testículo? (What causes human testicular cancer? in Spanish and English) Sociedad Iberoamericana de Información Científica 2005, February 2005.
35. Sahmoun AE, Case LD, Santoro TJ, **Schwartz GG**. Anatomical distribution of small cell lung cancer: Effects of lobe and gender on brain metastases and survival. Anticancer Research 2005, 25:1101-1108.
36. Sahmoun AE, Case ID, Jackson SA, **Schwartz GG**. (*corresponding author*) Cadmium and prostate cancer: A critical epidemiologic analysis. Cancer Investigation 2005, 23:256-263.
37. Il'yasova D, **Schwartz GG**. (*corresponding author*). Cadmium and renal cancer. Toxicology and Applied Pharmacology 2005, 207: 179-186.
39. **Schwartz GG**. Vitamin D and the epidemiology of prostate cancer. Seminars in Dialysis 2005, 18:276-289.

40. John EM, **Schwartz GG**, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D gene polymorphisms and risk of advanced prostate cancer. Cancer Research 2005, 65:5470-5479.
41. **Schwartz GG**, Hall MC, Patton S, Lee WR, Stindt D, Lovato J, Torti FM. A Phase I/II trial of 19-nor-1 α ,25-Dihydroxyvitamin D₂ (Paricalcitol) in advanced androgen insensitive prostate cancer. Clinical Cancer Research 2005; 11, 8680-8685.
42. Lim H-S, Roychoudhuri R, Peto J, **Schwartz G**, Baade P, Møller H. Cancer survival depends on season of diagnosis and sunlight exposure. International Journal of Cancer 2006, 119: 1530-1536.
43. **Schwartz GG**, Hanchette CL. UV, latitude, and prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes & Control 2006,17: 1091-1101.
44. **Schwartz GG**, Skinner HG. Vitamin D and cancer: New insights. Current Opinion in Clinical Nutrition and Metabolic Care, 2007, 10: 6-11.
45. Houston DK, Cesari M, Ferrucci L, Cherubini A, Maggio D, Bartali B, Johnson M, **Schwartz GG**, Kritchevsky SB. Association between vitamin D status and physical performance: The InCHIANTI study. Journal of Gerontology, Medical Sciences, 2007; 62A: 440-446.
46. Molnar I, Stark N, Lovato J, Powell B, Cruz J, Hurd DD, Chen TC, Holick MF, Cambra S, McQuellon RP, **Schwartz GG** (*corresponding author*). Treatment of low-risk myelodysplastic syndromes with high dose oral cholecalciferol (2,000 – 4,000 IU) Vitamin D₃. Leukemia, 2007, 21: 1089-1092.
47. John E, Koo J, **Schwartz GG**. Sun exposure and prostate cancer risk: Evidence for a protective effect of early life exposure. Cancer Epidemiology, Biomarkers and Prevention, 2007;16:1283-1286.
48. **Schwartz GG**. The “Cocaine Blues” and other problems in epidemiologic studies of vitamin D and cancer. Nutrition Reviews 2007, 65: S75-S76.
49. John EJ, **Schwartz GG**, Koo J, Ingles SA. Sun exposure, Vitamin D Receptor gene polymorphisms and breast cancer risk in a multiethnic population. American Journal of Epidemiology 2007, 166:1409-1419.
50. **Schwartz GG**. Prostate cancer, serum Parathyroid Hormone and the progression of skeletal metastases. Cancer Epidemiology Biomarkers & Prevention, 2008, 17: 478-83.
51. **Schwartz GG**, Eads D, Naczki C, Northrup S, Chen TC, Koumenis C 19-nor-1 α ,25-Dihydroxyvitamin D₂ (Paricalcitol) inhibits the proliferation of human pancreatic cancer cells *in vitro* and *in vivo*. Cancer Biology & Therapy, 2008, 7: 430-436.

Book Chapters

1. **Schwartz GG**, Rosenblum LA. Primate infancy: Problems and developmental strategies. In: Wolman B (Ed), Handbook of Developmental Psychology, Englewood Cliffs: Prentice-Hall, 1982, pp. 63-75.
2. **Schwartz GG**, Rosenblum LA. Sneezing behavior and its biological significance. In: Handbook of Squirrel Monkey Research, Plenum Press, 1985, pp. 169-186.
3. **Schwartz GG**, Rosenblum LA. Allometric influences of primate mothers and infants. In: Rosenblum LA & Moltz H (Eds.), Symbiosis in Parent-Offspring Interaction. New York: Plenum Press, 1985, pp. 253-269.
4. **Schwartz GG**. Chromosome aberrations. In: Hulka BS, Wilcosky TW, Griffiths JD (Eds), Biological Markers in Epidemiology. New York: Oxford University Press, 1990, pp. 147-172.
5. **Schwartz GG**. Oncogenes: A primer for epidemiologists. In: Hulka BS, Wilcosky TW, Griffiths JD (Eds), Biological Markers in Epidemiology. New York: Oxford University Press, 1990, pp. 173-195.
6. **Schwartz GG**. Prostate Cancer and the Vitamin D Hypothesis. In: Michael Holick & Ernst G. Jung (Eds), Biological Effects of Light, deGruyter, Berlin, 1996, pp. 309-316.
7. **Schwartz GG**. Lokeshwar, B.L., Selzer, M.G., Block, N.L., Binderup, L. $1\alpha,25$ -(OH) $_2$ Vitamin D and EB1089 inhibit prostate cancer metastasis in vivo. In: Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone. 1997, pp. 489-490.
8. **Schwartz GG**. Prostate cancer and vitamin D: From concept to clinic. A 10-year update. In: A.W., Norman, R. Bouillon, Thomasset M., Vitamin D Endocrine System. University of California Press, 2000, 445-452.
9. Chen TC, Whitlatch L, Young M, Flanagan J, **Schwartz GG**, Lokeshwar BL, Kong X, Zhu X, Holick MF. Enhancement of 25-Hydroxyvitamin D- 1α -Hydroxylase activity in prostate cells by gene transfection: A novel approach for the treatment of prostate cancer. In: A.W, Norman, R. Bouillon, Thomasset M., Vitamin D Endocrine System. University of California Press, 2000, 525-528.
10. **Schwartz GG**. Vitamin D and the Big Three: Cancers of the Colon, Breast, and Prostate. In: M.F. Holick (Ed.), Biological Effects of Light 2002, Kluwer, Amsterdam, 2002, 255 - 265.
11. Young MV, Whitlatch LW, **Schwartz GG**, Flanagan JN, Burnstein KL, Lokeshwar BL, Holick MF, Chen TC. A reduced 25-Hydroxyvitamin D- 1α -Hydroxylase activity in human prostate cancer cells can be restored by gene transfer. In M.F. Holick (Ed.), Biological Effects of Light 2002, Kluwer, Amsterdam, 2002, 277-280.
12. **Schwartz GG**, Chen TC. Vitamin D, sunlight, and the natural history of prostate cancer. In Feldman D, Pike JW, Glorieux FH (eds.), Vitamin D (2nd Edition), Elsevier, San Diego, CA, 2005, 1599-1615.